Research and Markets: Global Ovarian Cancer Drugs Market 2011-2015: Patent Expiration of Key Drugs Could Pose a …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/gh388z/global_ovarian_can) has announced the addition of the "Global Ovarian Cancer Drugs Market 2011-2015" report to their offering.

TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of ovarian cancer. The Global Ovarian Cancer Drugs market has also been witnessing the trend of the use of combination therapies for the treatment of ovarian cancer.

Commenting on the report, an analyst from TechNavio's Healthcare team said; ''The current trend witnessed by the Global Ovarian Cancer Drugs market is the use of combination therapies for the treatment of ovarian cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and the destruction of cancerous cells. The combination is chosen according to the size of the tumor and the risk of recurrence.''

According to the report, globally, there has been an increase in the number of women being diagnosed with ovarian cancer. The increase in the prevalence of ovarian cancer is owing to a variety of factors such as obesity, infertility, mutations in specific genes, early start of menstruation, and late start of menopause. Furthermore, the incidence of ovarian cancer increases with the rapidly expanding elderly population. Thus, with the increase in the prevalence of ovarian cancer, the demand for ovarian cancer drugs is also increasing.

Companies Mentioned

- Eli Lilly

- GlaxoSmithKline

- Bristol Myers Squibb

- Roche Pharmaceuticals

Visit link:
Research and Markets: Global Ovarian Cancer Drugs Market 2011-2015: Patent Expiration of Key Drugs Could Pose a ...